[
  {
    "ts": null,
    "headline": "HS market forecast to reach $7.8bn across 7MM by 2034",
    "summary": "This 15.6% CAGR is largely attributed to the launch of novel biologics and small molecules.",
    "url": "https://finnhub.io/api/news?id=9d3a8f241c84943d0d8ef74364b79b930b49776b7a999585099d01a51a2199e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753722584,
      "headline": "HS market forecast to reach $7.8bn across 7MM by 2034",
      "id": 136108042,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "This 15.6% CAGR is largely attributed to the launch of novel biologics and small molecules.",
      "url": "https://finnhub.io/api/news?id=9d3a8f241c84943d0d8ef74364b79b930b49776b7a999585099d01a51a2199e2"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
    "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
    "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720800,
      "headline": "Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.",
      "id": 136108043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.",
      "url": "https://finnhub.io/api/news?id=effbd36456b93069516cc1612f178c1d9cc51814939ac44278d6997b46475248"
    }
  },
  {
    "ts": null,
    "headline": "Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?",
    "summary": "ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.",
    "url": "https://finnhub.io/api/news?id=d5b48a20b1596483bffcf5b07b056d12b593a767dd165e45fed0992ca0894415",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753715760,
      "headline": "Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?",
      "id": 136108006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.",
      "url": "https://finnhub.io/api/news?id=d5b48a20b1596483bffcf5b07b056d12b593a767dd165e45fed0992ca0894415"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
    "summary": "Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=9ca3b1de056818c3e854d9f6659e6a4002503f17b5a53c1942d5a76070049dc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753712880,
      "headline": "Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
      "id": 136108008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=9ca3b1de056818c3e854d9f6659e6a4002503f17b5a53c1942d5a76070049dc7"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Dividend Stocks to Buy Right Now and Hold Forever",
    "summary": "Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors.",
    "url": "https://finnhub.io/api/news?id=0d7882ccc1bf37cf932ebf4b61c698d9d94625d2aae1be80fc5909c01ec3e19b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753711200,
      "headline": "2 Top Dividend Stocks to Buy Right Now and Hold Forever",
      "id": 136108046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors.",
      "url": "https://finnhub.io/api/news?id=0d7882ccc1bf37cf932ebf4b61c698d9d94625d2aae1be80fc5909c01ec3e19b"
    }
  },
  {
    "ts": null,
    "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
    "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
    "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753706498,
      "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
      "id": 136107253,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177313278/image_2177313278.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
      "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Rise Pre-Bell as US, EU Strike Trade Deal; Investors Await Key Tech Earnings, Economic Data, Fed Policy Decision",
    "summary": "The benchmark US stock measures were pointing higher before the opening bell Monday as the US and th",
    "url": "https://finnhub.io/api/news?id=8536387912871bd1a9e52604629f7e6d3f8467c9eaddf94775b2bc8711bf4e4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753701979,
      "headline": "Stocks Rise Pre-Bell as US, EU Strike Trade Deal; Investors Await Key Tech Earnings, Economic Data, Fed Policy Decision",
      "id": 136107951,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The benchmark US stock measures were pointing higher before the opening bell Monday as the US and th",
      "url": "https://finnhub.io/api/news?id=8536387912871bd1a9e52604629f7e6d3f8467c9eaddf94775b2bc8711bf4e4a"
    }
  },
  {
    "ts": null,
    "headline": "Option Volatility And Earnings Report For July 28 – Aug 1",
    "summary": "It’s a huge week for earnings this week with some big names set to report including Apple, Amazon, Microsoft, Meta Platforms, Robinhood Markets, Strategy Inc, Coinbase, UnitedHealth Group, Visa, Mastercard and Exxon Mobil.",
    "url": "https://finnhub.io/api/news?id=bf9995f703ab1a9ae1bbeefcd9e24734066ae702b5b9af3f70134132d8fd1f58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753700402,
      "headline": "Option Volatility And Earnings Report For July 28 – Aug 1",
      "id": 136107952,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "It’s a huge week for earnings this week with some big names set to report including Apple, Amazon, Microsoft, Meta Platforms, Robinhood Markets, Strategy Inc, Coinbase, UnitedHealth Group, Visa, Mastercard and Exxon Mobil.",
      "url": "https://finnhub.io/api/news?id=bf9995f703ab1a9ae1bbeefcd9e24734066ae702b5b9af3f70134132d8fd1f58"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% […]",
    "url": "https://finnhub.io/api/news?id=b6e1b43931528920d847642d3e3a607392dd3786d9a13df99130bdf4122aedde",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682890,
      "headline": "Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT",
      "id": 136108049,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% […]",
      "url": "https://finnhub.io/api/news?id=b6e1b43931528920d847642d3e3a607392dd3786d9a13df99130bdf4122aedde"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Positioned for Growth With Strong Skyrizi, Rinvoq Sales, Says JPMorgan",
    "summary": "AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s second-quarter earnings report, JPMorgan reaffirmed its Overweight rating and $200 price target on AbbVie Inc. (NYSE:ABBV) on July 10. Citing ongoing strength from Skyrizi and Rinvoq products as well as slight foreign exchange tailwinds that could […]",
    "url": "https://finnhub.io/api/news?id=2a05e7f0c70022219c72947ce8597b8c1b97649670ab11a027a1b6adaae66008",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753681344,
      "headline": "AbbVie (ABBV) Positioned for Growth With Strong Skyrizi, Rinvoq Sales, Says JPMorgan",
      "id": 136108050,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s second-quarter earnings report, JPMorgan reaffirmed its Overweight rating and $200 price target on AbbVie Inc. (NYSE:ABBV) on July 10. Citing ongoing strength from Skyrizi and Rinvoq products as well as slight foreign exchange tailwinds that could […]",
      "url": "https://finnhub.io/api/news?id=2a05e7f0c70022219c72947ce8597b8c1b97649670ab11a027a1b6adaae66008"
    }
  }
]